Toronto, ON – July 8, 2011 – Sanofi Pasteur, Canada's oldest and largest vaccine company, is proud to announce the official opening of a conference centre and historical gallery to celebrate its 97-year history. Named after the company’s founder, Dr. John G. FitzGerald, the facility features exhibits and artifacts chronicling the birth of Connaught Laboratories in 1914.

“The FitzGerald Conference Centre holds an important place in the history of public health in Canada,” said Mark Lievonen, President of Sanofi Pasteur Limited. “It housed the laboratories where Canada's first diphtheria vaccine was produced, and where groundbreaking discoveries in the production of insulin and polio vaccine were made. These milestones and many others are captured in an inspiring exhibit. Restoration of the building was completed in collaboration with the City of Toronto Heritage and Preservation Services authorities, and has brought the building back to its original glory.”

The conference centre is the oldest building on the Connaught Campus, aside from the Barton Avenue Stable which was moved from its original downtown location in 1935. The attractive two-storey laboratory originally included a large stable area with 22 horse stalls, an operating room and cold storage room. Dr. FitzGerald and his family resided on the second floor during the 1920s.

Dr. FitzGerald's grandson James FitzGerald, a renowned writer, said he is pleased to see his grandfather’s legacy preserved. “Through a diverse collection of old equipment, artifacts, photographs and documents, the centre honours the contributions of my grandfather and many other public health pioneers.  Sanofi Pasteur has done a wonderful job bringing its history to life.”

While the facility is not open to the public on a regular basis, tours can be arranged by appointment. For more information on how you can visit the Heritage Centre, please contact Nancy Simpson, Director of Communications at or by phone at 416-667-2955.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: or

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.



Global Media Relations   Canadian Media Relations
Pascal Barollier   Nancy Simpson
T. +33-(0)4-37-37-50-38   T. + 1-416-667-2955